<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665271</url>
  </required_header>
  <id_info>
    <org_study_id>844160</org_study_id>
    <nct_id>NCT04665271</nct_id>
  </id_info>
  <brief_title>Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS</brief_title>
  <official_title>Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bold Health Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess if a new digital app version of a self-help&#xD;
      intervention for Irritable Bowel Syndrome (IBS), is an acceptable and effective treatment for&#xD;
      improving the overall quality of life in patients with IBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the current study is to test the acceptability and efficacy of an updated digital&#xD;
      app for IBS patients. The design of the study is experimental. There will be two experimental&#xD;
      groups, an immediate treatment group and an active control group. Once consented and&#xD;
      enrolled, participants will be randomly assigned to either the immediate treatment group or&#xD;
      the active control group by the coin toss feature of random.org. Participants in the&#xD;
      immediate treatment group will be able to download the app at no cost. Participants in the&#xD;
      control group will be given access to an education and relaxation training control app at no&#xD;
      cost to them. At 8 weeks after enrollment, all participants in both groups will receive a&#xD;
      battery of follow-up questionnaires (the same that they answered directly after consenting in&#xD;
      the beginning of the study as baseline measures). Upon receipt of the 8 week questionnaire&#xD;
      data, participants in the control group will be given access to the Zemedy app. After having&#xD;
      had access to the app for 8 weeks, control participants will be asked to complete another set&#xD;
      of questionnaires. All participants will receive 3 month post-treatment follow-up&#xD;
      questionnaires. The research method is experimental, cross over (randomized controlled trial)&#xD;
      with a control control. Participation in the study will last approximately 4.5 months,&#xD;
      depending on the subjects willingness to participate and rate of completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Active control with cross-over at post-treatment and three month follow-up</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritable Bowel Syndrome Quality of Life (IBSQoL)</measure>
    <time_frame>8 weeks</time_frame>
    <description>IBS specific health related quality of life measure. Scale scores range from 0-100 with higher scores reflecting more impairment (worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Gastrointestinal Symptom Rating Scale. Scale scores range from 0-78 with high scores representing worse GI symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI-Cognitions Questionnaire (GICog)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale measures distorted, catastrophic beliefs about the social and occupational implications of having gastrointestinal symptoms. Scale scores range from 0 to 64 with higher scores representing worse outcomes (more distorted, catastrophic beliefs about GI symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral Sensitivity Index (VSI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale measures anxiety about visceral (gut) sensations. Scale scores range from 0 to 75 with higher scores representing more anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of Food Questionnaire (FFQ)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale measures fear of food and aversive consequences of eating. Scale scores range from 0-90 with higher scores representing more fear and impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures depressive symptoms. Scale scores range from 0 to 63 with higher scores representing more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures occupational impairment stemming from a health condition. scores range from 0 to 30 with higher scores representing more impairment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Immediate Treatment - Zemedy App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given immediate access to the Zemedy app for IBS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control - Education and Relaxation Training App</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given access to a education and relaxation training app. After 8 weeks they will then be crossed over to the Zemedy app.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Zemedy App</intervention_name>
    <description>Digital smart phone app that delivers cognitive-behavioral therapy for IBS</description>
    <arm_group_label>Active Control - Education and Relaxation Training App</arm_group_label>
    <arm_group_label>Immediate Treatment - Zemedy App</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-report of physician diagnosis of IBS.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe depression or suicidality&#xD;
&#xD;
          -  Comorbid GI disorder such as inflammatory bowel disease or celiac disease.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa G Hunt, PhD</last_name>
    <phone>6105298055</phone>
    <email>mhunt@psych.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anika Dalvie</last_name>
    <phone>925-389-0722</phone>
    <email>asdalvie@sas.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa G Hunt</last_name>
      <phone>215-898-6478</phone>
      <email>mhunt@psych.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Melissa Hunt, PhD</investigator_full_name>
    <investigator_title>Associate Director of Clinical Training</investigator_title>
  </responsible_party>
  <keyword>cognitive behavioral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT04665271/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT04665271/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

